[
  {
    "row_id": "LBA33",
    "regimen": "ctDNA-guided anti-EGFR rechallenge strategy",
    "drugs": [
      "EGFR",
      "ctDNA"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "CITRIC"
  },
  {
    "row_id": "LBA32",
    "regimen": "Panitumumab retreatment followed by regorafenib",
    "drugs": [
      "Panitumumab",
      "Regorafenib"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "723O",
    "regimen": "liquid biopsy-guided treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 2",
    "trial_id": "PEGASUS"
  },
  {
    "row_id": "775P",
    "regimen": "Neoadjuvant Chemotherapy and Short Course Radiation Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "MIBC",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "SPADE"
  },
  {
    "row_id": "1018eTiP",
    "regimen": "Oral MYB Transcription Factor Inhibitor",
    "drugs": [
      "RGT-61159"
    ],
    "biomarkers": [],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1486",
    "regimen": "improve drug development",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1213",
    "regimen": "biomarker analysis and molecular subtyping",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_823",
    "regimen": "Optimizing Treatment Options",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1158",
    "regimen": "liquid biopsy in CRC",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_509",
    "regimen": "RAS/RAF blockade",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_88",
    "regimen": "MSI-H/dMMR CRC",
    "drugs": [],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_94",
    "regimen": "BMS Therapeutic Pipeline",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1MO",
    "regimen": "Placental features overexpression",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "724O",
    "regimen": "comparison of outcomes in clinical trials",
    "drugs": [],
    "biomarkers": [
      "dMMR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "CN42",
    "regimen": "Screening Adherence Drives Cost-Effectiveness",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "745P",
    "regimen": "secondary resection of metastases",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2323P",
    "regimen": "non-OS endpoints",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1744",
    "regimen": "Cell proliferation and DNA repair defects",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "769P",
    "regimen": "Liquid Biopsy in Stage II Colon Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "853P",
    "regimen": "anti-EGFR resistance mutations in RAS/BRAF-wild type left-sided metastatic colorectal cancer",
    "drugs": [
      "cetuximab"
    ],
    "biomarkers": [
      "RAS",
      "BRAF"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "CRC01"
  },
  {
    "row_id": "892eP",
    "regimen": "Emerging trends of early-onset colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "740P",
    "regimen": "Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC)",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "HIPECT4"
  },
  {
    "row_id": "2942eP",
    "regimen": "incidence of cardiotoxicity in the treatment of colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "810P",
    "regimen": "Multimodal Treatment on Sexual Function in Patients with Rectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "787P",
    "regimen": "organ preservation approach in patients with locally advanced rectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "CHORD"
  },
  {
    "row_id": "886eP",
    "regimen": "impact of RAS and BRAF mutations on immunotherapy outcomes",
    "drugs": [],
    "biomarkers": [
      "RAS",
      "BRAF",
      "MSI",
      "dMMR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "848P",
    "regimen": "Treatment pathways and efficacy outcomes of patients with metastatic colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "PROMETCO"
  },
  {
    "row_id": "885eP",
    "regimen": "Hepatic arterial infusion chemotherapy (HAIC) as intensification or salvage treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2882P",
    "regimen": "Malignant Bowel Obstruction in Advanced Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "782P",
    "regimen": "Neoadjuvant therapy for Locally Advanced Rectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "840P",
    "regimen": "Circulating Biomarkers in Primary and Metastatic Colorectal Cancer Patients",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "821P",
    "regimen": "Functional precision medicine using MicroOrganoSpheres",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "850P",
    "regimen": "Short-term fasting vs. individualized nutrition during chemotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "901eP",
    "regimen": "Tertiary lymphoid structures (TLSs) in metastatic colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "811P",
    "regimen": "Safety and tolerability of fruquintinib",
    "drugs": [
      "fruquintinib"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1932",
    "regimen": "Immunotherapy in MSS/pMMR colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "878eP",
    "regimen": "impact of a novel liquid biopsy blood test on PROMs and PREMs",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1",
    "regimen": "Anti-EGFR Monoclonal Antibodies",
    "drugs": [
      "Anti-EGFR Monoclonal Antibodies"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "846P",
    "biomarkers": []
  },
  {
    "row_id": "2",
    "regimen": "mCapOX plus cetuximab",
    "drugs": [
      "mCapOX",
      "cetuximab",
      "mFOLFOX6"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "800P",
    "biomarkers": []
  },
  {
    "row_id": "3",
    "regimen": "sirexatamab plus bevacizumab and chemotherapy",
    "drugs": [
      "sirexatamab",
      "bevacizumab",
      "chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "LBA34",
    "biomarkers": []
  },
  {
    "row_id": "4",
    "regimen": "Zanzalintinib plus atezolizumab",
    "drugs": [
      "Zanzalintinib",
      "atezolizumab",
      "regorafenib"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "LBA30",
    "biomarkers": []
  },
  {
    "row_id": "5",
    "regimen": "Not specified",
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "842P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "6",
    "regimen": "Conversion Surgery",
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "827P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "7",
    "regimen": "Not specified",
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "734MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "8",
    "regimen": "panitumumab vs bevacizumab",
    "drugs": [
      "panitumumab",
      "bevacizumab"
    ],
    "population": "mCRC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "826P",
    "biomarkers": []
  },
  {
    "row_id": "9",
    "regimen": "Encorafenib + cetuximab + binimetinib",
    "drugs": [
      "Encorafenib",
      "cetuximab",
      "binimetinib"
    ],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "839P",
    "biomarkers": []
  },
  {
    "row_id": "10",
    "regimen": "pertuzumab + trastuzumab",
    "drugs": [
      "pertuzumab",
      "trastuzumab"
    ],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "738P",
    "biomarkers": []
  },
  {
    "row_id": "11",
    "regimen": "A Multicenter-Derived Nodal Classification System for Colon Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "820P"
  },
  {
    "row_id": "12",
    "regimen": "sirexatamab plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy",
    "drugs": [
      "sirexatamab",
      "bevacizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "LBA34"
  },
  {
    "row_id": "13",
    "regimen": "Utilizing circulating tumor DNA methylation as postoperative surveillance for colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "765P"
  },
  {
    "row_id": "14",
    "regimen": "Zanzalintinib plus atezolizumab vs regorafenib in previously treated metastatic colorectal cancer",
    "drugs": [
      "zanzalintinib",
      "atezolizumab",
      "regorafenib"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "LBA30"
  },
  {
    "row_id": "15",
    "regimen": "Diagnostic Accuracy of Circulating Tumor DNA-Based Liquid Biopsy for Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1743P"
  },
  {
    "row_id": "16",
    "regimen": "Towards achieving full MSI reflex testing in CRC, GC and EC",
    "drugs": [],
    "biomarkers": [
      "MSI"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1756eP"
  },
  {
    "row_id": "17",
    "regimen": "Real-World Characteristics and Outcomes",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "873eP"
  },
  {
    "row_id": "18",
    "regimen": "SSGJ-707 targeting PD-1 and VEGF with chemotherapy",
    "drugs": [
      "SSGJ-707"
    ],
    "biomarkers": [
      "PD-1",
      "VEGF"
    ],
    "modality": [
      "Bispecific",
      "Chemotherapy"
    ],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "796P"
  },
  {
    "row_id": "19",
    "regimen": "immunotherapy impact on mCRC",
    "drugs": [],
    "biomarkers": [
      "mismatch repair"
    ],
    "modality": [
      "IO"
    ],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "900eP"
  },
  {
    "row_id": "20",
    "regimen": "Short-course Radiotherapy followed by Chemotherapy and PD-L1 inhibitor",
    "drugs": [],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "Radiotherapy",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "779P"
  },
  {
    "row_id": "739P",
    "regimen": "microsatellite instability detection",
    "drugs": [],
    "biomarkers": [
      "MSI"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "739P"
  },
  {
    "row_id": "2959eP",
    "regimen": "EGFR-targeted monoclonal antibodies",
    "drugs": [
      "EGFR-targeted monoclonal antibodies"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2959eP"
  },
  {
    "row_id": "891eP",
    "regimen": "anti-BRAF and anti-EGFR therapy",
    "drugs": [
      "anti-BRAF",
      "anti-EGFR"
    ],
    "biomarkers": [
      "BRAF V600E"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "891eP"
  },
  {
    "row_id": "802P",
    "regimen": "immunotherapy with pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "biomarkers": [
      "MSI-H",
      "MSI"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "802P"
  },
  {
    "row_id": "752P",
    "regimen": "randomized trial of adjuvant therapy",
    "drugs": [
      "atezolizumab"
    ],
    "biomarkers": [
      "dMMR",
      "PD-L1"
    ],
    "modality": [],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "752P"
  },
  {
    "row_id": "834P",
    "regimen": "AI-Driven Colorectal Cancer Risk Stratification",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "834P"
  },
  {
    "row_id": "2881P",
    "regimen": "Total Neoadjuvant Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "2881P"
  },
  {
    "row_id": "2365P",
    "regimen": "Community-based Survivorship Care",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2365P"
  },
  {
    "row_id": "797P",
    "regimen": "Irinotecan Liposome combined with 5-FU/LV and Bevacizumab",
    "drugs": [
      "Irinotecan Liposome",
      "5-FU",
      "LV",
      "Bevacizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "797P"
  },
  {
    "row_id": "763P",
    "regimen": "blood-based multiplex methylation assay",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "763P"
  },
  {
    "row_id": "907eTiP",
    "regimen": "fecal microbiota transplantation plus QL1706 plus Bevacizumab plus XELOX",
    "drugs": [
      "QL1706",
      "Bevacizumab",
      "XELOX"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "907eTiP"
  },
  {
    "row_id": "864eP",
    "regimen": "second recurrence after resection",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "864eP"
  },
  {
    "row_id": "841P",
    "regimen": "dose-escalation study evaluating ginisortamab",
    "drugs": [
      "ginisortamab",
      "5-fluorouracil"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1/2",
    "trial_id": "841P"
  },
  {
    "row_id": "777P",
    "regimen": "chemoradiotherapy followed by immune checkpoint blockade",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "777P"
  },
  {
    "row_id": "803P",
    "regimen": "Neo BRAF wild-type metastatic colorectal cancer",
    "drugs": [],
    "biomarkers": [
      "BRAF wild-type"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "803P"
  },
  {
    "row_id": "2964eP",
    "regimen": "serum substance P level prediction",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2964eP"
  },
  {
    "row_id": "762P",
    "regimen": "incident colorectal cancer associated with smoking",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "762P"
  },
  {
    "row_id": "760P",
    "regimen": "incidence of primary colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "760P"
  },
  {
    "row_id": "852P",
    "regimen": "Neoadjuvant Options in Synchronous mCRC",
    "drugs": [],
    "biomarkers": [
      "RAS mutated",
      "RAS wild type"
    ],
    "modality": [],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "852P"
  },
  {
    "row_id": "785P",
    "regimen": "Neoadjuvant Chemotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "785P"
  },
  {
    "row_id": "870eP",
    "regimen": "local radical therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "870eP"
  },
  {
    "row_id": "880eP",
    "regimen": "Encorafenib + Cetuximab",
    "drugs": [
      "Encorafenib",
      "Cetuximab"
    ],
    "biomarkers": [
      "BRAF V600E"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "880eP"
  },
  {
    "row_id": "890eP",
    "regimen": "Trifluridine-Tipiracil with or without Bevacizumab",
    "drugs": [
      "Trifluridine-Tipiracil",
      "Bevacizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "890eP"
  },
  {
    "row_id": "814P",
    "regimen": "anti-EGFR therapy",
    "drugs": [],
    "biomarkers": [
      "RAS",
      "BRAF V600E"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "814P"
  },
  {
    "row_id": "793P",
    "regimen": "induction chemotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "793P"
  },
  {
    "row_id": "792P",
    "regimen": "Frontline Anti-VEGF and Anti-EGFR Exposure",
    "drugs": [
      "Trifluridine/Tipiracil",
      "Bevacizumab",
      "Regorafenib"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "792P"
  },
  {
    "row_id": "851P",
    "regimen": "Botensilimab, Balstilimab and Regorafenib",
    "drugs": [
      "Botensilimab",
      "Balstilimab",
      "Regorafenib"
    ],
    "biomarkers": [
      "MSS"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "851P"
  },
  {
    "row_id": "869eP",
    "regimen": "Incidence of Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "869eP"
  },
  {
    "row_id": "764P",
    "regimen": "tumor-informed molecular residual disease detection",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "764P"
  },
  {
    "row_id": "776P",
    "regimen": "predictive factors for severe toxicities",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "776P"
  },
  {
    "row_id": "1597eTiP",
    "regimen": "Personalised Tumour Trained Lymphocytes",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase I/IIa",
    "trial_id": "1597eTiP"
  },
  {
    "row_id": "2197P",
    "regimen": "Return to Work After Curative Cancer Treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2197P"
  },
  {
    "row_id": "899eP",
    "regimen": "Individualized Triplet Chemotherapy Decision-Making",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "899eP"
  },
  {
    "row_id": "784P",
    "regimen": "prediction of metastatic lymph nodes",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "784P"
  },
  {
    "row_id": "731MO",
    "regimen": "Telisotuzumab adizutecan + Bevacizumab vs SOC",
    "drugs": [
      "Telisotuzumab adizutecan",
      "Bevacizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "3L",
    "phase": "Not specified",
    "trial_id": "731MO"
  },
  {
    "row_id": "909eTiP",
    "regimen": "AMB-05X for ctDNA(+) colorectal cancer",
    "drugs": [
      "AMB-05X"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "909eTiP"
  },
  {
    "row_id": "766P",
    "regimen": "tissue-agnostic approach for detecting MRD",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "766P"
  },
  {
    "row_id": "808P",
    "regimen": "Tumor Microenvironment Heterogeneity and Resistance Mechanisms to HER2 Inhibition",
    "drugs": [],
    "biomarkers": [
      "HER2"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "808P"
  },
  {
    "row_id": "795P",
    "regimen": "Optimizing Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "795P"
  },
  {
    "row_id": "744P",
    "regimen": "Validating ARCAD-Derived External Control Arms",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "744P"
  },
  {
    "row_id": "868eP",
    "regimen": "Robotic-Assisted, Laparoscopic and Open Surgery",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "832P",
    "regimen": "First-line Metastatic Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "PLATFORM-B"
  },
  {
    "row_id": "902eTiP",
    "regimen": "DPD phenotype-guided dose individualization of fluoropyrimidine-based chemotherapy",
    "drugs": [
      "fluoropyrimidine"
    ],
    "biomarkers": [
      "DPD"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "730MO",
    "regimen": "Trifluridine/Tipiracil with Capecitabine and Bevacizumab",
    "drugs": [
      "Trifluridine",
      "Tipiracil",
      "Capecitabine",
      "Bevacizumab"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "TriComB"
  },
  {
    "row_id": "790P",
    "regimen": "Induction chemotherapy with mDCF prior to Chemoradiotherapy",
    "drugs": [
      "mDCF"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "761P",
    "regimen": "Early-Onset Colorectal Cancer Study",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "898eP",
    "regimen": "Fruquintinib alternating with Bevacizumab plus Capecitabine",
    "drugs": [
      "Fruquintinib",
      "Bevacizumab",
      "Capecitabine"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Maintenance",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "2334P",
    "regimen": "Socioeconomic Status and Overall Survival in Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "911eTiP",
    "regimen": "Node-sparing modified Short-Course Radiation with CAPOX and Sintilimab",
    "drugs": [
      "CAPOX",
      "Sintilimab"
    ],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "836P",
    "regimen": "Immunotherapy-Based Total Neoadjuvant Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "887eP",
    "regimen": "SBRT Combined with Immune Checkpoint Inhibitors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "894eP",
    "regimen": "Global Disease Burden of Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "733P",
    "regimen": "Atezolizumab with or without Tiragolumab following neoadjuvant chemoradiotherapy",
    "drugs": [
      "Atezolizumab",
      "Tiragolumab",
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "NEOTE"
  },
  {
    "row_id": "741P",
    "regimen": "Chemoradiotherapy followed by tislelizumab and CAPOX",
    "drugs": [
      "tislelizumab",
      "CAPOX"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "RELIEVE-01"
  },
  {
    "row_id": "877eP",
    "regimen": "Non‚ÄêAlcoholic Fatty Liver Disease and Risk of Early-Onset Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "863eP",
    "regimen": "Impact of Inflammatory Status on Quality of Life in Advanced Colorectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "905eTiP",
    "regimen": "CAPOX plus PD-1 inhibitor with or without short-course radiotherapy",
    "drugs": [
      "CAPOX",
      "PD-1 inhibitor"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "TORCH-iTNT"
  },
  {
    "row_id": "783P",
    "regimen": "Neoadjuvant envafolimab combined with chemoradiotherapy",
    "drugs": [
      "envafolimab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "Not specified"
  },
  {
    "row_id": "LBA31",
    "regimen": "Neoadjuvant immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "754P",
    "regimen": "Predicting sex-specific subsequent primary extracolonic cancer risks",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "ROW_3432",
    "regimen": "Current treatment strategies",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "3065eP",
    "regimen": "HLA loss of heterozygosity in colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_3544",
    "regimen": "Early CRC Treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_3585",
    "regimen": "Multidisciplinary treatment approaches",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "6P",
    "regimen": "Patient-Derived Organoid Assays",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1764eP",
    "regimen": "Multi-omic liquid biopsy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA9",
    "regimen": "ctDNA-Guided Adjuvant Chemotherapy De-Escalation",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "AGITG DYNAMIC-III"
  },
  {
    "row_id": "287eP",
    "regimen": "Comprehensive genomic profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "32eP",
    "regimen": "Exosomal miR-382-5p inhibits pre-metastatic niche formation",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "726O",
    "regimen": "Combined Analysis of Pathologists and AI",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_3962",
    "regimen": "Positioning later line treatment options",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1772eP",
    "regimen": "Blood-only, Targeted Methylation ctDNA Assay",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "156P",
    "regimen": "FOLFOXIRI/bevacizumab combined with nivolumab",
    "drugs": [
      "FOLFOXIRI",
      "bevacizumab",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1736eP",
    "regimen": "Treatment Sequence in Advanced Small Bowel Neuroendocrine Neoplasms",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "251eP",
    "regimen": "Integrative cfDNA Fragmentation and Methylation Profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "7P",
    "regimen": "Spatial single-cell imaging and transcriptomic profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "670P",
    "regimen": "Intra-CSF delivery of Dual CD19/CD22 CAR-T Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "CAR-T"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4196",
    "regimen": "Time to address liver transplantation",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA29",
    "regimen": "Nivolumab plus ipilimumab vs nivolumab monotherapy",
    "drugs": [
      "nivolumab",
      "ipilimumab"
    ],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4300",
    "regimen": "Introduction and welcome",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4301",
    "regimen": "Immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4302",
    "regimen": "Targeting KRAS and TGFbeta",
    "drugs": [],
    "biomarkers": [
      "KRAS",
      "TGFbeta"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4330",
    "regimen": "Nursing management of side effects",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "266eP",
    "regimen": "Nelmastobart plus Capecitabine",
    "drugs": [
      "Nelmastobart",
      "Capecitabine"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Phase Ib/II",
    "phase": "Phase 1",
    "trial_id": "266eP"
  },
  {
    "row_id": "ROW_4422",
    "regimen": "Supporting adherence and monitoring",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "56eP",
    "regimen": "Targeting the RMI2-RAD51 Axis",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "56eP"
  },
  {
    "row_id": "143P",
    "regimen": "Spatial Heterogeneity of the Immune Microenvironment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "143P"
  },
  {
    "row_id": "ROW_4660",
    "regimen": "Refining patient selection for regional therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4661",
    "regimen": "Discussion",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "881eP",
    "regimen": "neoadjuvant chemoradiotherapy (nCRT) combined with camrelizumab",
    "drugs": [
      "camrelizumab"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "EV-302",
    "biomarkers": []
  },
  {
    "row_id": "858P",
    "regimen": "Exploring antigen presentation and Wnt/beta-Catenin pathway alterations",
    "drugs": [],
    "biomarkers": [
      "Microsatellite",
      "MSI"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "889eP",
    "regimen": "adjuvant treatment",
    "drugs": [],
    "modality": [],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "849P",
    "regimen": "Pro-inflammatory Immune Cell Infiltration",
    "drugs": [],
    "biomarkers": [
      "Consensus Molecular Subtype"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "806P",
    "regimen": "biparatopic anti-HER2 antibody conjugate (ADC)",
    "drugs": [
      "JSKN003"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "845P",
    "regimen": "Liposomal irinotecan combined with capecitabine and bevacizumab",
    "drugs": [
      "liposomal irinotecan",
      "capecitabine",
      "bevacizumab"
    ],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "882eP",
    "regimen": "Intratumoural IVX037",
    "drugs": [
      "IVX037"
    ],
    "biomarkers": [
      "CD55",
      "KRAS"
    ],
    "modality": [
      "Vaccine"
    ],
    "population": "Other",
    "line": "",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "833P",
    "regimen": "Real-World Survival Outcomes Stratified by Oncogene Expression",
    "drugs": [],
    "biomarkers": [
      "Oncogene Expression"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "801P",
    "regimen": "Prognostic and Predictive Value of ctDNA-MSI",
    "drugs": [],
    "biomarkers": [
      "ctDNA",
      "MSI"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "838P",
    "regimen": "ginisortamab (UCB6114) with trifluridine/tipir",
    "drugs": [
      "ginisortamab",
      "trifluridine",
      "tipir"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 1/2",
    "trial_id": ""
  },
  {
    "row_id": "830P",
    "regimen": "Liver fat in relation to clinical outcomes",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "893eP",
    "regimen": "Boarding time as a predictor of short-term mortality",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "856P",
    "regimen": "Patterns of care and treatment in Elderly patients with resected Colon Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "876eP",
    "regimen": "Temporal and age-related patterns in mode of presentation for colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "732MO",
    "regimen": "ctDNA clearance and correlation with outcome",
    "drugs": [],
    "biomarkers": [
      "ctDNA"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "788P",
    "regimen": "Neoadjuvant Chemotherapy in Rectal Cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "867eP",
    "regimen": "Impact of Wnt/beta-catenin signalling on CAR-T cell cytotoxicity",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "CAR-T"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "747P",
    "regimen": "Regorafenib plus Irinotecan",
    "drugs": [
      "Regorafenib",
      "Irinotecan"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "N/A",
    "biomarkers": []
  },
  {
    "row_id": "912eTiP",
    "regimen": "SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy",
    "drugs": [
      "SCRT",
      "mFOLFOX6",
      "PD-1 Antibody"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "CRIT",
    "biomarkers": []
  },
  {
    "row_id": "819P",
    "regimen": "AI-based blood test",
    "population": "Other",
    "line": "N/A",
    "phase": "Not specified",
    "trial_id": "N/A",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "727MO",
    "regimen": "FOLFOX plus PANITUMUMAB",
    "drugs": [
      "FOLFOX",
      "PANITUMUMAB"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "N/A",
    "biomarkers": []
  },
  {
    "row_id": "872eP",
    "regimen": "Identifying fit-for-use real-world data",
    "population": "Other",
    "line": "N/A",
    "phase": "Not specified",
    "trial_id": "AZUR-1",
    "drugs": [],
    "biomarkers": [
      "MSI",
      "dMMR"
    ]
  },
  {
    "row_id": "2921eP",
    "regimen": "Medical oral nutrition supplement",
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "NUTRACT",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "854P",
    "regimen": "Immunonutrition",
    "population": "Other",
    "line": "N/A",
    "phase": "Not specified",
    "trial_id": "N/A",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "750P",
    "regimen": "Dynamic ctDNA in Predicting Response to Neoadjuvant Chemotherapy",
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "CONVERT",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "828P",
    "regimen": "Enhance immune checkpoint inhibitor efficacy",
    "population": "Other",
    "line": "N/A",
    "phase": "Not specified",
    "trial_id": "N/A",
    "drugs": [],
    "biomarkers": [
      "MSI"
    ]
  },
  {
    "row_id": "735P",
    "regimen": "Adjuvant aspirin for colorectal cancers",
    "drugs": [
      "Aspirin"
    ],
    "biomarkers": [
      "PIK3CA"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "ASCOLT"
  },
  {
    "row_id": "771P",
    "regimen": "ctDNA-negative resection",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "NCT06562348",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "737MO",
    "regimen": "Trastuzumab deruxtecan (T-DXd)",
    "drugs": [
      "Trastuzumab deruxtecan"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "DESTINY-CRC02",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "861TiP",
    "regimen": "ctDNA guided palliative systemic therapy",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "NCT06562348",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "825P",
    "regimen": "Oxaliplatin-Based Chemotherapy + Targeted Agents",
    "drugs": [
      "Oxaliplatin"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "ARCAD D",
    "biomarkers": []
  },
  {
    "row_id": "786P",
    "regimen": "Serplulimab Combined with CapeOX and Celecoxib",
    "drugs": [
      "Serplulimab",
      "CapeOX",
      "Celecoxib"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "SCAR",
    "biomarkers": []
  },
  {
    "row_id": "746P",
    "regimen": "Zanidatamab + mFOLFOX6 +/- Bevacizumab",
    "drugs": [
      "Zanidatamab",
      "mFOLFOX6",
      "Bevacizumab"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "817P",
    "regimen": "anti-EGFR Therapy",
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "823P",
    "regimen": "mFOLFOXIRI Following Metastasectomy",
    "drugs": [
      "mFOLFOXIRI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "FANTASTIC",
    "biomarkers": []
  },
  {
    "row_id": "866eP",
    "regimen": "toripalimab, cetuximab plus FOLFIRI",
    "drugs": [
      "toripalimab",
      "cetuximab",
      "FOLFIRI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "Tesla study",
    "biomarkers": []
  },
  {
    "row_id": "773P",
    "regimen": "Cadonilimab into Total Neoadjuvant Therapy",
    "drugs": [
      "Cadonilimab"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "906eTiP",
    "regimen": "neoadjuvant PD-1 vaccine PD1-Vaxx",
    "drugs": [
      "PD1-Vaxx"
    ],
    "modality": [
      "Vaccine"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "Neo-POLEM",
    "biomarkers": [
      "MSI"
    ]
  },
  {
    "row_id": "742P",
    "regimen": "real world matched study",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "Survival of patients with dMMR versus pMMR early stage colon cancer",
    "drugs": [],
    "biomarkers": [
      "dMMR"
    ]
  },
  {
    "row_id": "875eP",
    "regimen": "first line combination chemotherapy",
    "drugs": [
      "EGFR-inhibitors",
      "VEGF-inhibitors"
    ],
    "biomarkers": [
      "EGFR"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Increased EGFR gene copy number (GCN) in prediction of outcome"
  },
  {
    "row_id": "815P",
    "regimen": "Microsatellite Instability Assessment",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "Prospective Evaluation of Deepath-MSI for Microsatellite Instability Assessment",
    "drugs": [],
    "biomarkers": [
      "MSI"
    ]
  },
  {
    "row_id": "813P",
    "regimen": "ACTION HIV",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "A LATAM Record of Patients with Anal Squamous Cell Carcinoma with and without HIV Infection",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "871eP",
    "regimen": "Molecular Profiles and Genomic Therapy",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "Molecular Profiles and Genomic Therapy in Young vs. Average-Onset Gastrointestinal (GI) Cancers",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "897eP",
    "regimen": "chemoradiation",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "Patient-reported quality of life after treatment with chemoradiation in patients with non-metastatic anal squamous cell carcinoma",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "812P",
    "regimen": "nivolumab and ipilimumab",
    "drugs": [
      "nivolumab",
      "ipilimumab"
    ],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "The PRODIGE-74 GERCOR NIPISAFE randomized non-comparati"
  },
  {
    "row_id": "879eP",
    "regimen": "nivolumab and ipilimumab",
    "drugs": [
      "nivolumab",
      "ipilimumab"
    ],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "GERCOR NIPIRESCUE phase II trial"
  },
  {
    "row_id": "831P",
    "regimen": "Cadonilimab Combined with FOLFOXIRI and Bevacizumab",
    "drugs": [
      "Cadonilimab",
      "FOLFOXIRI",
      "Bevacizumab"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "Cadonilimab Combined with FOLFOXIRI and Bevacizumab as First-Line Treatment for MSS/pMMR Metastatic Colorectal Cancer",
    "biomarkers": []
  },
  {
    "row_id": "1534P",
    "regimen": "BTN1A1-Targeted Immunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "855P",
    "regimen": "Larotrectinib in NTRK Fusion-Positive Colorectal Cancer",
    "drugs": [
      "Larotrectinib"
    ],
    "biomarkers": [
      "NTRK"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "888eP",
    "regimen": "Bi-specific T cell engager (BiTE) activity in Colorectal Cancer",
    "drugs": [],
    "biomarkers": [
      "EpCAM"
    ],
    "modality": [
      "Bispecific"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "768P",
    "regimen": "Adjuvant chemotherapy by ctDNA-based genomic profile",
    "drugs": [],
    "biomarkers": [
      "ctDNA"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "837P",
    "regimen": "BRAF-Targeted Therapy in Pretreated Colorectal Cancer",
    "drugs": [],
    "biomarkers": [
      "TP53"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "770P",
    "regimen": "ctDNA Testing for Adjuvant Chemotherapy Decision-Making",
    "drugs": [],
    "biomarkers": [
      "ctDNA"
    ],
    "modality": [],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "757P",
    "regimen": "Not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "757P"
  },
  {
    "row_id": "986P",
    "regimen": "NovoTTF-100L(P) in Combination with Chemotherapy",
    "drugs": [
      "NovoTTF-100L(P)",
      "Chemotherapy"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "986P"
  },
  {
    "row_id": "847P",
    "regimen": "Not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "847P"
  },
  {
    "row_id": "ROW_2804",
    "regimen": "immunotherapy in early-stages colon cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "ROW_2804"
  },
  {
    "row_id": "805P",
    "regimen": "UGT1A1 genotype-guided irinotecan dosing",
    "drugs": [
      "irinotecan"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "805P"
  },
  {
    "row_id": "772P",
    "regimen": "Perioperative atezolizumab with or without IMM-101",
    "drugs": [
      "atezolizumab",
      "IMM-101"
    ],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Perioperative",
    "phase": "Not specified",
    "trial_id": "772P"
  },
  {
    "row_id": "794P",
    "regimen": "Fruquintinib Expanded Access Program",
    "drugs": [
      "Fruquintinib"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "mCRC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "794P"
  },
  {
    "row_id": "767P",
    "regimen": "Not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "767P"
  },
  {
    "row_id": "884eP",
    "regimen": "Not specified",
    "drugs": [],
    "biomarkers": [
      "Interleukin-1beta",
      "Interleukin-6"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "884eP"
  },
  {
    "row_id": "873eP",
    "regimen": "Not specified",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "873eP"
  },
  {
    "row_id": "ROW_3321",
    "trial_id": "ROW_3321",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_3360",
    "trial_id": "ROW_3360",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1756eP",
    "trial_id": "1756eP",
    "drugs": [],
    "biomarkers": [
      "MSI"
    ]
  },
  {
    "row_id": "ROW_4303",
    "trial_id": "ROW_4303",
    "drugs": [],
    "biomarkers": []
  }
]